Connor, Clark & Lunn Investment Management Ltd. Travere Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 685,511 shares of TVTX stock, worth $19.1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

685,511

Previous 495,177 38.44%

Holding current value

$19.1 Million

Previous $8.87 Million 14.34%

% of portfolio

0.04%

Previous 0.04%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	$13.49 - $21.54 $2.57 Million - $4.1 Million	190,334 Added 38.44%	685,511 $10.1 Million
Q1 2025 May 12, 2025	BUY	$17.07 - $23.75 $1.17 Million - $1.63 Million	68,451 Added 16.04%	495,177 $8.87 Million
Q4 2024 Feb 10, 2025	SELL	$13.65 - $19.85 $1.35 Million - $1.96 Million	-98,655 Reduced 18.78%	426,726 $7.43 Million
Q3 2024 Nov 08, 2024	BUY	$7.89 - $15.21 $418,051 - $805,901	52,985 Added 11.22%	525,381 $7.35 Million
Q2 2024 Aug 09, 2024	BUY	$5.26 - $8.28 $293,208 - $461,552	55,743 Added 13.38%	472,396 $3.88 Million
Q1 2024 May 09, 2024	BUY	$7.18 - $9.82 $925,085 - $1.27 Million	128,842 Added 44.77%	416,653 $3.21 Million
Q4 2023 Feb 09, 2024	SELL	$5.44 - $9.5 $16,439 - $28,709	-3,022 Reduced 1.04%	287,811 $2.59 Million
Q3 2023 Nov 13, 2023	SELL	$7.64 - $17.25 $595 - $1,345	-78 Reduced 0.03%	290,833 $2.6 Million
Q2 2023 Aug 10, 2023	BUY	$15.3 - $22.61 $212,654 - $314,256	13,899 Added 5.02%	290,911 $4.47 Million
Q1 2023 May 09, 2023	BUY	$17.82 - $22.89 $573,804 - $737,058	32,200 Added 13.15%	277,012 $6.23 Million
Q4 2022 Feb 10, 2023	SELL	$18.47 - $26.14 $37,623 - $53,247	-2,037 Reduced 0.83%	244,812 $5.15 Million
Q3 2022 Nov 10, 2022	BUY	$22.91 - $28.63 $213,017 - $266,201	9,298 Added 3.91%	246,849 $6.08 Million
Q2 2022 Aug 05, 2022	BUY	$20.94 - $30.01 $37,210 - $53,327	1,777 Added 0.75%	237,551 $5.76 Million
Q1 2022 May 12, 2022	BUY	$23.61 - $30.6 $127,612 - $165,393	5,405 Added 2.35%	235,774 $6.08 Million
Q4 2021 Feb 10, 2022	BUY	$24.34 - $31.17 $1.51 Million - $1.94 Million	62,119 Added 36.92%	230,369 $7.15 Million
Q3 2021 Nov 12, 2021	BUY	$12.98 - $25.03 $2.18 Million - $4.21 Million	168,250 New	168,250 $4.08 Million
Q1 2021 May 13, 2021	SELL	$23.37 - $31.77 $289,507 - $393,566	-12,388 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $237,477 - $345,253	12,388 New	12,388 $338,000

Others Institutions Holding TVTX

# of Institutions

232

Shares Held

101M

Call Options Held

1.71M

Put Options Held

401K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.79B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Travere Therapeutics, Inc. Transaction History